Replies to post #107200 on Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

from the PR:

" will present data on a) the development of a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic biomarker during PD-1 blockade treatment with pembrolizumab and b) the correlation of changes in T cell populations with the clinical activity observed in the ongoing ADXS-503 clinical trial"

I'd hardly expect any results beyond what's already been presented. It takes time for the data to mature, and with the very slow progress (6 patients so far), this will take years and years to get to Ph 3 if ever. Can we be all surprised? It's possible, but sans any surprise development (a sudden PR or, G-d forbid - a CR!) we tank. I expect we revisit low 0.30 or see even low 0.20s by the end of May. A R/S and more dilution in June.